Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.

Dose and secondary cancer risk of the breast and thyroid during high dose rate (HDR) brachytherapy for 100 gynaecological cancer patients have been estimated. The organ doses were measured using LiF thermoluminescence dosimeters LiF (TLD-100). Patient demographic data (i.